Madrigal Pharmaceuticals (FRA:YDO1) Earnings per Share (Diluted)

: €-18.53 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Madrigal Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was €-5.25. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.53.

Madrigal Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was €-5.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.53.

Madrigal Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was €-5.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.53.

Madrigal Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Madrigal Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

-4.91

-10.76

-12.95

-16.27

-18.33

Madrigal Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)																-4.70	-3.95	-4.33	-5.00	-5.25

Competitive Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's PE Ratio falls into.

Madrigal Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Madrigal Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-342.619	-	0)	/	18.688
	=	-18.33

Madrigal Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-102.882	-	0)	/	19.773
	=	-5.20

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18.53

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Madrigal Pharmaceuticals (FRA:YDO1) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Madrigal Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals (FRA:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

MDGL:USA

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (FRA:YDO1) Headlines

No Headlines